This innovative clinical research project aims to test a non-antibiotic triple therapy for the treatment of Travellers’ Diarrhoea (TD). This is a common occurrence when UK residents visit parts of the world such as India and South East Asia as well as South America. In China, TD is very common and the first line treatment is antibiotic therapy. This is an unnecessary use of valuable life saving antibiotics and so one major aim of our trial is to establish if our test treatment could replace antibiotic therapy ie be antibiotic sparing. Devised by Dr David Brown, previously a Trustee and chair of ANTRUK’s Science Committee, as a result of literature mining, the triple therapy consists of one over the counter pharmaceutical drug and two nutraceuticals obtained from health food shops, The triple therapy is given orally and in a few case studies has been proven to be effective in treating TD sometimes within 30 minutes. In order to speed up recruitment and keep costs low, the trial known as DIAMOND (DIarrhea Antibiotic Management using Over-the-counter Nutraceuticals in Daily practice) is being undertaken at Shanghai Jiading District Center Hospital, Shanghai, China.
The DIAMOND trial collaborators are Dr Jessika Hu (University of Hong Kong), Professor Paul Little, Dr Merlin Wilcox and Professor Michael Moore (University of Southampton), Dr David Brown (Alchemy Biomedical Consulting), Dr Xudong Zhou and colleagues at Zhejiang University and ANTRUK. As of June 2018, Ethics Committee approval has been obtained and recruitment is scheduled to commence in Q3 / Q4 2018 with the final results available by Q1 2019. Funding is being provided by ANTRUK jointly with Dr David Brown. For more information contact email@example.com